Melanocyte receptors: Clinical implications and therapeutic relevance

被引:48
作者
Carlson, J. Andrew
Linette, Gerald P.
Aplin, Andrew
Ng, Bernard
Slominski, Andrzej
机构
[1] Albany Med Coll, Dept Pathol & Lab Med, Div Dermatopathol & Dermatol, Albany, NY 12208 USA
[2] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA
[3] Albany Med Coll, Ctr Cell Biol & Canc Biol, Albany, NY 12208 USA
[4] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA
关键词
D O I
10.1016/j.det.2007.06.005
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The activation or the inhibition of melanocyte-specific receptors offers novel means of augmenting normal melanocyte function, skin color, and photoprotection, or treating melanocytic disorders, namely at this time, metastatic melanoma. Melanocyte-specific receptors include melanocortin-1 (MCR1) and melatonin receptors. Other receptors that play an important role in melanoma progression are G-protein couple receptors such as Frizzled 5 and receptor tyrosine kinases such as c-Kit and hepatocyte growth factor (HGF) receptor. These receptors activate two crucial cell-signaling pathways, RAS/RAF/MEK/ERK and PI3K/AKT, integral to melanoma cell survival, and can serve as targets for therapy of disseminated melanoma. Activation of death receptors is another pathway that can be exploited with targeted therapeutics to control advanced melanoma. This article reviews the current understanding of melanocyte receptors, their agonists and inhibitors, and their potential to treat the melanocytic pathology.
引用
收藏
页码:541 / +
页数:19
相关论文
共 141 条
[1]   The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation [J].
Abdel-Malek, Z ;
Scott, MC ;
Suzuki, I ;
Tada, A ;
Im, S ;
Lamoreux, L ;
Ito, S ;
Barsh, G ;
Hearing, VJ .
PIGMENT CELL RESEARCH, 2000, 13 :156-162
[2]   Melanoma prevention strategy based on using tetrapeptide α-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity [J].
Abdel-Malek, Zalfa A. ;
Kadekaro, Ana Luisa ;
Kavanagh, Renny J. ;
Todorovic, Aleksandar ;
Koikov, Leonid N. ;
McNulty, Joseph C. ;
Jackson, Pilgrim J. ;
Millhauser, Glenn L. ;
Schwemberger, Sandy ;
Babcock, George ;
Haskell-Luevano, Carrie ;
Knittel, James J. .
FASEB JOURNAL, 2006, 20 (09) :1561-+
[3]   Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature [J].
Adnane, Lila ;
Trail, Pamela A. ;
Taylor, Ian ;
Wilhelm, Scott M. .
REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 :597-+
[4]  
ALBELDA SM, 1990, CANCER RES, V50, P6757
[5]   Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes [J].
Alexeev, Vitali ;
Yoon, Kyonggeun .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (05) :1102-1110
[6]  
Aplin AE, 1998, PHARMACOL REV, V50, P197
[7]   Importance of P-cadherin, β-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma [J].
Bachmann, IM ;
Straume, O ;
Puntervoll, HE ;
Kalvenes, MB ;
Akslen, LA .
CLINICAL CANCER RESEARCH, 2005, 11 (24) :8606-8614
[8]   Chemokines in pathology and medicine [J].
Baggiolini, M .
JOURNAL OF INTERNAL MEDICINE, 2001, 250 (02) :91-104
[9]  
Berger Y, 2006, EXP BIOL MED, V231, P1111
[10]   Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B [J].
Berking, C ;
Takemoto, R ;
Satyamoorthy, K ;
Shirakawa, T ;
Eskandarpour, M ;
Hansson, J ;
VanBelle, PA ;
Elder, DE ;
Herlyn, M .
CANCER RESEARCH, 2004, 64 (03) :807-811